title: Efficacy of intracerebral delivery of cisplatin in combination with photon irradiation for treatment of brain tumors.
abstract: We have evaluated the efficacy of intracerebral (i.c.) convection-enhanced delivery (CED) of cisplatin in combination with photon irradiation for the treatment of F98 glioma-bearing rats. One thousand glioma cells were stereotactically implanted into the brains of Fischer rats and 13 days later cisplatin (6 microg/20 microl) was administered i.c. by CED at a flow rate of 0.5 microl/min. On the following day the animals were irradiated with a single 15 Gy dose of X-rays, administered by a linear accelerator (LINAC) or 78.8 keV synchrotron X-rays at the European Synchrotron Radiation Facility (ESRF). Untreated controls had a mean survival time (MST) + or - standard error of 24 + or - 1 days compared to >59 + or - 13 days for rats that received cisplatin alone with 13% of the latter surviving >200 days. Rats that received cisplatin in combination with either 6 MV (LINAC) or 78.8 keV (synchrotron) X-rays had almost identical MSTs of >75 + or - 18 and >74 + or - 19 days, respectively with 17 and 18% long-term survivors. Microscopic examination of the brains of long-term surviving rats revealed an absence of viable tumor cells and cystic areas at the presumptive site of the tumor. Our data demonstrate that i.c. CED of cisplatin in combination with external X-irradiation significantly enhanced the survival of F98 glioma-bearing rats. This was independent of the X-ray beam energy and probably was not due to the production of Auger electrons as we previously had postulated. Our data provide strong support for the approach of concomitantly administering platinum-based chemotherapy in combination with radiotherapy for the treatment of brain tumors. Since a conventional LINAC can be used as the radiation source, this should significantly broaden the clinical applicability of this approach compared to synchrotron radiotherapy, which could only be carried out at a very small number of specialized facilities.
authors.affiliation: INSERM U836, Equipe 6, ESRF, Medical Beamline, BP 220, 38043, Grenoble Cedex 9, France.
authors.forename: Julia
authors.initials: J
authors.lastname: Rousseau
authors.forename: Rolf F
authors.initials: RF
authors.lastname: Barth
authors.forename: Manuel
authors.initials: M
authors.lastname: Fernandez
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Adam
authors.forename: Jacques
authors.initials: J
authors.lastname: Balosso
authors.forename: François
authors.initials: F
authors.lastname: Estève
authors.forename: Hélène
authors.initials: H
authors.lastname: Elleaume
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D004307:Dose-Response Relationship, Radiation; D016503:Drug Delivery Systems / Q000379:methods; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D010315:Particle Accelerators; D017785:Photons / Q000627:therapeutic use*; D011878:Radiotherapy / Q000379:methods*; D051381:Rats; D011916:Rats, Inbred F344; D016019:Survival Analysis; D017356:Synchrotrons
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin